Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 8-K Event Regulation FD disclosure
  2. 4/A Open-market sale Director sold 20,000 shares at an average $33.83 ($676,583)
  3. 4 Returned to the company Director returned 60,000 shares (to the company)
  4. 4 Grant or award Director acquired 5,986 shares (grant or award)
  5. 4 Grant or award Director acquired 5,986 shares (grant or award)
  6. 4 Grant or award Director acquired 5,986 shares (grant or award)
  7. 4 Grant or award Director acquired 5,986 shares (grant or award)
  8. 4 Grant or award Director acquired 5,986 shares (grant or award)
  9. 4 Grant or award Director acquired 5,986 shares (grant or award)
  10. 4 Grant or award Director acquired 5,986 shares (grant or award)
  11. 4 Grant or award Director acquired 5,986 shares (grant or award)
  12. 8-K Event Shareholder vote results
  13. 10-Q Report Quarterly Report
  14. 8-K Event Results of operations
  15. DEFA14A Proxy Proxy Materials
  16. DEF 14A Proxy Proxy Statement
  17. 4 Open-market sale Director sold 20,000 shares at an average $33.83 ($676,583)
  18. 8-K Event Executive or director change
  19. 8-K Event Material agreement
  20. S-3ASR Offering Registration Statement

Page 19 of 40 · 789 filings